[HTML][HTML] Engineering CAR-T cells for next-generation cancer therapy
M Hong, JD Clubb, YY Chen - Cancer cell, 2020 - cell.com
T cells engineered to express chimeric antigen receptors (CARs) with tumor specificity have
shown remarkable success in treating patients with hematologic malignancies and …
shown remarkable success in treating patients with hematologic malignancies and …
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
S Rafiq, CS Hackett, RJ Brentjens - Nature reviews Clinical oncology, 2020 - nature.com
T cells genetically engineered to express chimeric antigen receptors (CARs) have proven—
and impressive—therapeutic activity in patients with certain subtypes of B cell leukaemia or …
and impressive—therapeutic activity in patients with certain subtypes of B cell leukaemia or …
NK cells for cancer immunotherapy
N Shimasaki, A Jain, D Campana - Nature reviews Drug discovery, 2020 - nature.com
Natural killer (NK) cells can swiftly kill multiple adjacent cells if these show surface markers
associated with oncogenic transformation. This property, which is unique among immune …
associated with oncogenic transformation. This property, which is unique among immune …
Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects
H Li, Y Yang, W Hong, M Huang, M Wu… - Signal transduction and …, 2020 - nature.com
Based on engineered or bacterial nucleases, the development of genome editing
technologies has opened up the possibility of directly targeting and modifying genomic …
technologies has opened up the possibility of directly targeting and modifying genomic …
The next generation of CRISPR–Cas technologies and applications
A Pickar-Oliver, CA Gersbach - Nature reviews Molecular cell biology, 2019 - nature.com
The prokaryote-derived CRISPR–Cas genome editing systems have transformed our ability
to manipulate, detect, image and annotate specific DNA and RNA sequences in living cells …
to manipulate, detect, image and annotate specific DNA and RNA sequences in living cells …
Treg cell-based therapies: challenges and perspectives
C Raffin, LT Vo, JA Bluestone - Nature Reviews Immunology, 2020 - nature.com
Cellular therapies using regulatory T (Treg) cells are currently undergoing clinical trials for
the treatment of autoimmune diseases, transplant rejection and graft-versus-host disease. In …
the treatment of autoimmune diseases, transplant rejection and graft-versus-host disease. In …
CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment
M Martinez, EK Moon - Frontiers in immunology, 2019 - frontiersin.org
Chimeric antigen receptor (CAR) T cells, T cells that have been genetically engineered to
express a receptor that recognizes a specific antigen, have given rise to breakthroughs in …
express a receptor that recognizes a specific antigen, have given rise to breakthroughs in …
Immunogenicity of CAR T cells in cancer therapy
DL Wagner, E Fritsche, MA Pulsipher… - Nature reviews Clinical …, 2021 - nature.com
Patient-derived T cells genetically reprogrammed to express CD19-specific chimeric antigen
receptors (CARs) have shown remarkable clinical responses and are commercially …
receptors (CARs) have shown remarkable clinical responses and are commercially …
Killing mechanisms of chimeric antigen receptor (CAR) T cells
MR Benmebarek, CH Karches, BL Cadilha… - International journal of …, 2019 - mdpi.com
Effective adoptive T cell therapy (ACT) comprises the killing of cancer cells through the
therapeutic use of transferred T cells. One of the main ACT approaches is chimeric antigen …
therapeutic use of transferred T cells. One of the main ACT approaches is chimeric antigen …
[HTML][HTML] Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with enhanced immune compatibility
H Xu, BO Wang, M Ono, A Kagita, K Fujii, N Sasakawa… - Cell stem cell, 2019 - cell.com
Induced pluripotent stem cells (iPSCs) have strong potential in regenerative medicine
applications; however, immune rejection caused by HLA mismatching is a concern. B2M …
applications; however, immune rejection caused by HLA mismatching is a concern. B2M …